466 | CAR‐T THERAPY WITH OX40 SIGNALING DRIVES CLONAL EXPANSION OF CD4+ T CELLS AND OVERCOMES IMMUNOSUPPRESSIVE MICROENVIRONMENT IN B‐CELL LYMPHOMA: A PHASE I TRIAL

Documenti analoghi

• 657 | TRANSPLANTATION IN COMBINATION WITH CAR‐T THERAPY FOR REFRACTORY/RELAPSED AGGRESSIVE B‐CELL LYMPHOMA AFTER FAILURE OF CD19 CAR‐T CELL THERAPY
  di: F. Yang, et al.
  Pubblicazione: (2025)
• 805 | PRE‐CLINICAL DEVELOPMENT OF CAR‐T CELLS TARGETING A LYTIC EBV ANTIGEN gp350 FOR THERAPY OF EBV‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA
  di: Y. Li, et al.
  Pubblicazione: (2025)
• 601 | TARGETING NAMPT AND BTK IN MANTLE CELL LYMPHOMA: TP53‐DEPENDENT SYNERGISTIC THERAPY
  di: Y. Liu, et al.
  Pubblicazione: (2025)
• 117 | DUAL TARGETING CD30/PDL‐1 CAR‐T CELLS OUTPERFORMS CD30 CAR‐T CELLS IN A NEWLY DEVELOPED IMMUNOSUPPRESSIVE 2D CELLULAR MODEL MIMICKING CLASSIC HL MICROENVIRONMENT
  di: N. Martarelli, et al.
  Pubblicazione: (2025)
• 831 | A PHASE 1, MULTICENTER, FIRST‐IN‐HUMAN TRIAL OF GCC2005, AN ALLOGENEIC CAR‐NK CELL THERAPY TARGETING CD5, IN PATIENTS WITH RELAPSED/REFRACTORY NK AND T‐CELL MALIGNANCIES
  di: W. S. Kim, et al.
  Pubblicazione: (2025)